Moleculin Annamycin Cardiac Safety Data

Moleculin Biotech announced new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the differentiated cardiac safety profile of its lead drug candidate, Annamycin. A pooled analysis across five completed clinical trials involving 90 patients with acute myeloid leukemia (AML) and soft tissue sarcoma demonstrated no detectable cardiotoxicity, even at cumulative exposure levels significantly exceeding traditional anthracycline dose limitations. This finding was independently validated by the Cleveland Clinic Division of Cardiovascular Medicine. The data reinforces Annamycin's potential to provide effective anthracycline-based therapy without the cumulative cardiac burden associated with currently prescribed agents, strengthening the rationale for Moleculin Biotech's ongoing pivotal Phase 2b/3 MIRACLE trial for relapsed or refractory AML. Previously reported efficacy from a Phase 1b/2 AML study showed a 50% complete remission rate and a 60% composite complete remission rate.